FOLH1 and prostate carcinoma: Using a ligand-targeting aptamer fused at its 3′-end to an siRNA duplex, these aptamer-siRNA chimeras (AsiCs) were first used to transfect and silence gene expression in prostate cancer cells both in vitro [136] and in vivo [137] using a prostate-membrane specific antigen (PSMA) aptamer.